Nestlé’s shareholders have a golden opportunity to call on the food giant to promote healthier lives in almost two hundred countries by backing a bold resolution at the multinational’s Annual General Meeting this week. Doing so can protect their profits in the long-haul. Backed by a coalition of five institutional investors with $ 1.68 trillion […] Continue reading ->
As many neglected tropical diseases (NTDs) spread via vectors like ticks or domestic mammals, human-centric prevention programmes alone are inadequate – and adopting more holistic approaches such as the routine vaccination of animals is logical.  This was the key message conveyed by health and policy experts at a panel discussion, “For a new approach to […] Continue reading ->
This article is the second in a three-part series on COVID-19 booster vaccines, which is an evolving discussion as more evidence emerges about the performance of vaccines against variants. Despite heated debates about doling out booster jabs in healthy people who are already fully vaccinated against SARS-CoV-2, there seems to be consensus that at least […] Continue reading ->
Nearly half of the 31 European nations using the European Union’s new digital COVID travel certificate have recognized the India-made version of the AstraZeneca vaccine, Covishield, alongside its European-made counterpart, Vaxzevria, an analysis by Health Policy Watch has revealed.  But other major countries, including France, Poland, and Italy, seem to be holding out, authorizing only […] Continue reading ->
Despite the emergence of new WHO concerns over quality control at Sputnik V’s domestic production facilities, the Russian Direct Investment Fund (RDIF) is pushing ahead with a massive international “open-license” manufacturing effort for its Sputnik V vaccine – which breaks the traditional model of vaccine production and leverages existing capacity in poorer countries, desperate for […] Continue reading ->
From Indonesia and the Seychelles, to Chile and China itself, there are some worrisome indications that the Chinese Sinopharm and Sinovac COVID vaccines sold by the hundreds of millions to vaccine-strapped low- and middle-income countries may not be performing as well as expected – particularly against rapidly spreading variants of SARS-CoV-2.   At the same time, […] Continue reading ->